EFFICACY AND TOLERABILITY OF 4-HYDROXYANDROSTENEDIONE (4-OHA) AS 1ST-LINE TREATMENT IN POSTMENOPAUSAL PATIENTS WITH BREAST-CANCER AFTER ADJUVANT THERAPY

被引:18
作者
BAJETTA, E
ZILEMBO, N
BUZZONI, R
NOBERASCO, C
CELIO, L
BICHISAO, E
机构
[1] Division of Medical Oncology B, Istituto Nazionale per to Studio e la Cura dei Tumori, Milan
关键词
D O I
10.1016/0305-7372(93)90005-C
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aromatase inhibitors are known to be effective in the treatment of advanced postmenopausal breast cancer. To assess the efficacy of the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) as first-line treatment in patients who were either resistant to or had relapsed after adjuvant therapy, 50 eligible patients received intramuscular 4-OHA either 250 mg or 500 mg fortnightly until disease progression or severe adverse events. Of the 43 patients evaluable for clinical response (UICC criteria), 15 (36%) showed objective response (CR+PR), 6 (14%) stable disease (SD). In relation to disease site, objective responses were obtained in 55% of cases with soft tissue metastases ( 16 29); in 33% with visceral metastases (8/24), and in 24% with bone involvement ( 5 21). In relation to previous adjuvant treatment, there were eight objective responses among the 17 patients treated with chemotherapy (47%), and seven objective responses among the 24 treated with tamoxifen (29%). The treatment was well tolerated. These results support the hypothesis that adjuvant therapy, whether hormonal or chemotherapy, may make patients less responsive to subsequent treatment. © 1993.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 15 条
[1]   10-YEAR EXPERIENCE WITH CMF-BASED ADJUVANT CHEMOTHERAPY IN RESECTABLE BREAST-CANCER [J].
BONADONNA, G ;
VALAGUSSA, P ;
ROSSI, A ;
TANCINI, G ;
BRAMBILLA, C ;
ZAMBETTI, M ;
VERONESI, U .
BREAST CANCER RESEARCH AND TREATMENT, 1985, 5 (02) :95-115
[2]  
BONADONNA G, 1991, SEMIN ONCOL, V18, P515
[3]   RESULTS OF SALVAGE HORMONAL-THERAPY AND SALVAGE CHEMOTHERAPY IN WOMEN FAILING ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY FOR BREAST-CANCER [J].
BUCKNER, JC ;
INGLE, JN ;
EVERSON, LK ;
OFALLON, JR ;
CULLINAN, SA ;
AHMANN, DL ;
KROOK, JE ;
PFEIFLE, DM .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (02) :135-142
[4]   LOW-DOSE AMINOGLUTETHIMIDE WITH AND WITHOUT HYDROCORTISONE REPLACEMENT AS A 1ST-LINE ENDOCRINE TREATMENT IN ADVANCED BREAST-CANCER - A PROSPECTIVE RANDOMIZED TRIAL OF THE ITALIAN ONCOLOGY GROUP FOR CLINICAL RESEARCH [J].
COCCONI, G ;
BISAGNI, G ;
CECI, G ;
BACCHI, M ;
BONI, C ;
BRUGIA, M ;
CARPI, A ;
DICOSTANZO, F ;
FRANCIOSI, V ;
GORI, S ;
INDELLI, M ;
PASSALACQUA, R .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :984-989
[5]  
COOMBES RC, 1992, EUR J CANCER, V28A, P1941
[6]  
FISHER B, 1992, SEMIN ONCOL, V19, P263
[7]  
FORNANDER T, 1987, CANCER TREAT REP, V71, P685
[8]  
GOSS PE, 1986, CANCER RES, V46, P4823
[9]   ASSESSMENT OF RESPONSE TO THERAPY IN ADVANCED BREAST-CANCER - PROJECT OF PROGRAM ON CLINICAL ONCOLOGY OF "INTERNATIONAL-UNION-AGAINST-CANCER, GENEVA, SWITZERLAND [J].
HAYWARD, JL ;
RUBENS, RD ;
CARBONE, PP ;
HEUSON, JC ;
KUMAOKA, S ;
SEGALOFF, A .
BRITISH JOURNAL OF CANCER, 1977, 35 (03) :292-298
[10]  
HOFFKEN K, 1990, J CLIN ONCOL, V8, P875